997 results on '"Engert, A."'
Search Results
2. How I treat nodular lymphocyte-predominant Hodgkin lymphoma
- Author
-
Eichenauer, Dennis A. and Engert, Andreas
- Published
- 2020
- Full Text
- View/download PDF
3. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
- Author
-
Reinke, Sarah, Bröckelmann, Paul J., Iaccarino, Ingram, Garcia-Marquez, Maria, Borchmann, Sven, Jochims, Franziska, Kotrova, Michaela, Pal, Karol, Brüggemann, Monika, Hartmann, Elena, Sasse, Stephanie, Kobe, Carsten, Mathas, Stephan, Soekler, Martin, Keller, Ulrich, Bormann, Matthias, Zimmermann, Andreas, Richter, Julia, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Schlößer, Hans, von Bergwelt-Baildon, Michael, Rosenwald, Andreas, Engert, Andreas, and Klapper, Wolfram
- Published
- 2020
- Full Text
- View/download PDF
4. Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment
- Author
-
Seifert, Nicole, primary, Reinke, Sarah, additional, Grund, Johanna, additional, Müller-Meinhard, Berit, additional, Engert, Andreas, additional, Borchmann, Peter, additional, Bröckelmann, Paul J, additional, Altenbuchinger, Michael, additional, and Klapper, Wolfram, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
- Author
-
Kobe, Carsten, Goergen, Helen, Baues, Christian, Kuhnert, Georg, Voltin, Conrad-Amadeus, Zijlstra, Josée, Hoekstra, Otto, Mettler, Jasmin, Drzezga, Alexander, Engert, Andreas, Borchmann, Peter, and Dietlein, Markus
- Published
- 2018
- Full Text
- View/download PDF
6. Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma
- Author
-
Sud, Amit, Thomsen, Hauke, Orlando, Giulia, Försti, Asta, Law, Philip J., Broderick, Peter, Cooke, Rosie, Hariri, Fadi, Pastinen, Tomi, Easton, Douglas F., Pharoah, Paul D.P., Dunning, Alison M., Peto, Julian, Canzian, Federico, Eeles, Rosalind, Kote-Jarai, ZSofia, Muir, Kenneth, Pashayan, Nora, Campa, Daniele, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, von Strandmann, Elke Pogge, Swerdlow, Anthony J., Engert, Andreas, Orr, Nick, Hemminki, Kari, and Houlston, Richard S.
- Published
- 2018
- Full Text
- View/download PDF
7. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
- Author
-
Eichenauer, Dennis A., Plütschow, Annette, Schröder, Lena, Fuchs, Michael, Böll, Boris, von Tresckow, Bastian, Diehl, Volker, Borchmann, Peter, and Engert, Andreas
- Published
- 2018
- Full Text
- View/download PDF
8. Balancing risk and benefit in early-stage classical Hodgkin lymphoma
- Author
-
Bröckelmann, Paul J., Sasse, Stephanie, and Engert, Andreas
- Published
- 2018
- Full Text
- View/download PDF
9. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
- Author
-
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, and Bastian von Tresckow
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
10. Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
- Author
-
Peter Borchmann, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Haenel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M. Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Peter Kamper, Daniel Molin, Stefanie Kreissl, Michael Fuchs, Gundolf Schneider, Andreas Rosenwald, Wolfram Klapper, Hans Eich, Christian Baues, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl, and Andreas Engert
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
11. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- Author
-
Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, Pogge von Strandmann, Elke, Borchmann, Peter, and Engert, Andreas
- Published
- 2015
- Full Text
- View/download PDF
12. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
- Author
-
Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L., and Younes, Anas
- Published
- 2015
- Full Text
- View/download PDF
13. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
- Author
-
Bröckelmann, Paul J, primary, Bühnen, Ina, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Herhaus, Peter, additional, Halbsguth, Teresa V, additional, Schaub, Valdete, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Bormann, Matthias, additional, Dickhut, Andreas, additional, Kaul, Helen, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Baues, Christian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
- Author
-
Borchmann, Peter, primary, Moccia, Alden, additional, Greil, Richard, additional, Hertzberg, Mark, additional, Schaub, Valdete, additional, Hüttmann, Andreas, additional, Keil, Felix, additional, Dierlamm, Judith, additional, Haenel, Mathias, additional, Novak, Urban, additional, Meissner, Julia, additional, Zimmermann, Andreas, additional, Mathas, Stephan, additional, Zijlstra, Josée M., additional, Fosså, Alexander, additional, Viardot, Andreas, additional, Hertenstein, Bernd, additional, Martin, Sonja, additional, Giri, Pratyush, additional, Kamper, Peter, additional, Molin, Daniel, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Schneider, Gundolf, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Eich, Hans, additional, Baues, Christian, additional, Hallek, Michael, additional, Dietlein, Markus, additional, Kobe, Carsten, additional, Diehl, Volker, additional, and Engert, Andreas, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
- Author
-
Eichenauer, Dennis A., Thielen, Indra, Haverkamp, Heinz, Franklin, Jeremy, Behringer, Karolin, Halbsguth, Teresa, Klimm, Beate, Diehl, Volker, Sasse, Stephanie, Rothe, Achim, Fuchs, Michael, Böll, Boris, von Tresckow, Bastian, Borchmann, Peter, and Engert, Andreas
- Published
- 2014
- Full Text
- View/download PDF
16. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
- Author
-
Hartmann, Sylvia, Eichenauer, Dennis A., Plütschow, Annette, Mottok, Anja, Bob, Roshanak, Koch, Karoline, Bernd, Heinz-Wolfram, Cogliatti, Sergio, Hummel, Michael, Feller, Alfred C., Ott, German, Möller, Peter, Rosenwald, Andreas, Stein, Harald, Hansmann, Martin-Leo, Engert, Andreas, and Klapper, Wolfram
- Published
- 2013
- Full Text
- View/download PDF
17. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy
- Author
-
Straka, Christian, Sandherr, Michael, Salwender, Hans, Wandt, Hannes, Metzner, Bernd, Hübel, Kai, Silling, Gerda, Hentrich, Marcus, Franke, Daniel, Schwerdtfeger, Rainer, Freund, Mathias, Sezer, Orhan, Giagounidis, Alexander, Ehninger, Gerhard, Grimminger, Wolfgang, Engert, Andreas, Schlimok, Günter, Scheid, Christof, Hellmann, Peter, Heinisch, Harald, Einsele, Hermann, Hinke, Axel, and Emmerich, Bertold
- Published
- 2011
- Full Text
- View/download PDF
18. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis
- Author
-
Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann-Grill, Karolin, additional, Kobbe, Guido, additional, Wilhelm, Martin, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William Hermann, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch-Ulrich, Kathleen, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J, additional
- Published
- 2021
- Full Text
- View/download PDF
19. PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group
- Author
-
Fuchs, Michael, primary, Jacob, Anne Sophie, additional, Kaul, Helen, additional, Kobe, Carsten, additional, Pabst, Thomas, additional, Greil, Richard, additional, Eichenauer, Dennis A., additional, Topp, Max, additional, Just, Marianne, additional, Hertenstein, Bernd, additional, Schaub, Valdete, additional, Vogelhuber, Martin, additional, Zijlstra, Josée M, additional, Plütschow, Annette, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study
- Author
-
Eichenauer, Dennis A., primary, Bühnen, Ina, additional, Fuchs, Michael, additional, Kaul, Helen, additional, Kobe, Carsten, additional, Hartmann, Sylvia, additional, Baues, Christian, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional
- Published
- 2021
- Full Text
- View/download PDF
21. Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
- Author
-
Ahmed, Sairah, primary, Flinn, Ian W., additional, Mei, Matthew, additional, Riedell, Peter A., additional, Armand, Philippe, additional, Grover, Natalie S, additional, Engert, Andreas, additional, Lapteva, Natalia, additional, Nadler, Paul I., additional, Myo, Aung, additional, and Heslop, Helen E., additional
- Published
- 2021
- Full Text
- View/download PDF
22. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
- Author
-
Halbsguth, Teresa V., Nogová, Lucia, Mueller, Horst, Sieniawski, Michal, Eichenauer, Dennis A., Schober, Thomas, Nisters-Backes, Hiltrud, Borchmann, Peter, Diehl, Volker, Engert, Andreas, and Josting, Andreas
- Published
- 2010
- Full Text
- View/download PDF
23. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
- Author
-
Kobe, Carsten, Dietlein, Markus, Franklin, Jeremy, Markova, Jana, Lohri, Andreas, Amthauer, Holger, Klutmann, Susanne, Knapp, Wolfram H., Zijlstra, Josee M., Bockisch, Andreas, Weckesser, Matthias, Lorenz, Reinhard, Schreckenberger, Mathias, Bares, Roland, Eich, Hans T., Mueller, Rolf-Peter, Fuchs, Michael, Borchmann, Peter, Schicha, Harald, Diehl, Volker, and Engert, Andreas
- Published
- 2008
- Full Text
- View/download PDF
24. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
- Author
-
Hagenbeek, Anton, Gadeberg, Ole, Johnson, Peter, Møller Pedersen, Lars, Walewski, Jan, Hellmann, Andrzej, Link, Brian K., Robak, Tadeusz, Wojtukiewicz, Marek, Pfreundschuh, Michael, Kneba, Michael, Engert, Andreas, Sonneveld, Pieter, Flensburg, Mimi, Petersen, Jørgen, Losic, Nedjad, and Radford, John
- Published
- 2008
- Full Text
- View/download PDF
25. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)
- Author
-
Sieniawski, Michal, Reineke, Thorsten, Nogova, Lucia, Josting, Andreas, Pfistner, Beate, Diehl, Volker, and Engert, Andreas
- Published
- 2008
- Full Text
- View/download PDF
26. How I treat nodular lymphocyte-predominant Hodgkin lymphoma
- Author
-
Andreas Engert and Dennis A. Eichenauer
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,CD30 ,medicine.medical_treatment ,Immunology ,Population ,Biochemistry ,Autologous stem-cell transplantation ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,education ,CD20 ,Chemotherapy ,education.field_of_study ,Relative survival ,biology ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,Combined Modality Therapy ,Hodgkin Disease ,Lymphoma ,Radiation therapy ,biology.protein ,business - Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte-predominant cells in NLPHL are consistently positive for CD20, but do not express CD30. The clinical course of NLPHL is indolent in the majority of cases. Most patients present with early-stage disease at the initial diagnosis. First-line treatment of stage IA NLPHL usually consists of limited-field radiotherapy alone. Patients with early-stage NLPHL other than stage IA and intermediate-stage disease mostly receive combined-modality treatment, whereas individuals with advanced NLPHL are treated with chemotherapy alone. In relapsed NLPHL, conventional chemotherapy, anti-CD20 antibodies, and radiotherapy represent active treatment modalities. Only patients with poor-risk characteristics such as early disease recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy and autologous stem cell transplantation. The overall and relative survival of patients with NLPHL is excellent as indicated by a low excess mortality compared with the general population. This article discusses treatment options for patients with NLPHL and factors that influence the choice of therapy on the basis of the available data and 2 clinical cases.
- Published
- 2020
27. Balancing risk and benefit in early-stage classical Hodgkin lymphoma
- Author
-
Paul J Bröckelmann, Andreas Engert, and Stephanie Sasse
- Subjects
Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Vincristine ,Dacarbazine ,Immunology ,Vinblastine ,Bleomycin ,Procarbazine ,Risk Assessment ,Biochemistry ,Disease-Free Survival ,03 medical and health sciences ,chemistry.chemical_compound ,Sex Factors ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Brentuximab vedotin ,Cyclophosphamide ,Survival rate ,Etoposide ,Neoplasm Staging ,business.industry ,Age Factors ,Cell Biology ,Hematology ,Hodgkin Disease ,Chemotherapy regimen ,Survival Rate ,030104 developmental biology ,chemistry ,Doxorubicin ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Prednisone ,Female ,Nivolumab ,business ,medicine.drug - Abstract
With defined chemotherapy and radiotherapy (RT) and risk-adapted treatment, early-stage classical Hodgkin lymphoma (HL) has become curable in a majority of patients. Hence, a major current goal is to reduce treatment-related toxicity while maintaining long-term disease control. Patients with early-stage favorable disease (ie, limited stage without risk factors [RFs]) are frequently treated with 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (2×ABVD) followed by 20-Gy involved-field or involved-site RT (IF/ISRT). In patients with early-stage unfavorable disease (ie, limited stage with RFs), 4 cycles of chemotherapy are usually consolidated with 30-Gy IF/ISRT. Compared with 4×ABVD, 2 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (2×BEACOPPescalated) followed by 2×ABVD improved 5-year progression-free survival (PFS), with similar 5-year overall survival. Recently, treatment strategies based on [18F]fluorodeoxyglucose positron emission tomography (PET) response were evaluated. In early-stage unfavorable HL, a majority of patients achieved a negative interim PET after 2×ABVD and an excellent outcome after 4×ABVD, whereas in those with a positive interim PET, 2×BEACOPPescalated improved 5-year PFS. Furthermore, a PET-guided RT approach was evaluated to decrease long-term toxicity. Although both the RAPID and H10 trials reported poorer disease control without RT, PET-guided omission of RT can constitute a valid therapeutic option in patients with an increased risk of RT-associated toxicity (eg, because of sex, age, or disease localization). Implementation of drugs such as the anti-CD30 antibody-drug conjugate brentuximab vedotin or the anti–programmed death 1 antibodies nivolumab or pembrolizumab might allow further reduction of overall mortality and improve quality of life in affected patients.
- Published
- 2018
28. Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
- Author
-
Matthew Mei, Sairah Ahmed, Philippe Armand, Natalia Lapteva, Natalie S Grover, Aung Myo, Andreas Engert, Ian W. Flinn, Peter A. Riedell, Helen E. Heslop, and Paul I. Nadler
- Subjects
Oncology ,medicine.medical_specialty ,CD30 ,business.industry ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,Refractory ,Internal medicine ,Chariot ,medicine ,Classical Hodgkin lymphoma ,CAR T-cell therapy ,In patient ,business - Abstract
Introduction CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has been transformative in B-cell lymphoid malignancies. CD30 is a validated target for classical Hodgkin Lymphoma (cHL), as demonstrated by the activity of the anti-CD30 antibody drug conjugate, brentuximab vedotin (BV), making it an attractive target for CAR-T therapy in this disease. In two Phase 1/2 clinical studies, autologous CD30-directed CAR-T-cell (CD30.CAR-T) therapy was well tolerated, with significant clinical activity (72% overall response rate [ORR] and 59% complete response [CR] rate) in relapsed or refractory (R/R) cHL patients after fludarabine-based lymphodepleting (LD) chemotherapy (Ramos et al., 2020). We report here the results of the Pilot segment of a Phase 2 Pivotal trial of autologous CD30.CAR-T in patients with R/R cHL (NCT#04268706). Methods This is a Phase 2 single arm, multi-center, multi-national study (U.S. and Europe), enrolling patients (12-75 years) with cHL who have progressed after at least 3 lines of therapy, including chemotherapy, BV, and anti-programmed cell death (PD)-1 antibodies. Previous autologous and/or allogeneic hematopoietic stem cell transplantation (HSCT) is allowed. The study is divided into two parts: a Pilot segment including at minimum 12 patients (for which accrual is complete) and a Pivotal segment planned to enroll approximately 82 patients to obtain at least 67 CD30.CAR-T-treated patients. Eligible patients undergo leukapheresis for manufacture of CD30.CAR-T cells, followed by LD chemotherapy using bendamustine and fludarabine, prior to infusion of CD30.CAR-T with an allowable dose range of 2.0 to 2.7 × 10 8 CD30.CAR-T cells per m 2. Bridging therapy was allowed. Safety is the primary endpoint in the Pilot portion, while ORR as assessed by an Independent Radiology Review Committee per the Lugano criteria (Cheson et al., 2014) is the primary endpoint in the Pivotal segment. Results As of 15 July 2021, 17 patients were screened and 15 patients enrolled in the Pilot segment (median age: 35 years [21-57], 66.7% male). The median number of prior therapies was 6, with a range of 4 to 19. Bridging therapy was given in 33.3% of patients. CD30.CAR-T product was successfully manufactured for all patients with a median manufacturing time of 6.3 weeks (5.9-8.0). Of 15 patients enrolled, 14 patients were eligible for treatment with CD30.CAR-T. To date, 12 patients have been treated, with CD30.CAR-T doses ranging from 2.2 to 2.7 × 10 8 cells/m 2. CD30.CAR-T treatment was well tolerated with the most common toxicities reported being hematologic adverse events (AEs)-related to LD chemotherapy. Majority of the AEs were Grade 1-2 anemia, neutropenia and thrombocytopenia. 12.5% of patients had Grade 3 anemia, neutropenia or thrombocytopenia. Other LD-related toxicities include Grade 1-2 nausea, anemia, fatigue, anorexia, gastrointestinal disorder and headache. CD30.CAR-T-related toxicities include Grade 1 cytokine release syndrome and maculopapular rash (reported in the same patient), and Grade 2 ventricular tachycardia in 1 patient. The ORR at Day 42 after CD30.CAR-T infusion, as assessed by investigators, was 100% (5/5). CR and partial response (PR) rates were observed in 4 (80%) and 1 (20%) patients, respectively. Pharmacokinetic analyses of CD30.CAR-T are ongoing. Conclusion Preliminary data from the Pilot segment of this study confirms favorable safety profile and excellent anti-tumor responses of CD30.CAR-T in heavily-treated R/R cHL patients. The efficacy and safety of CD30.CAR-T will be further evaluated in the Pivotal segment of this Phase 2 study. Figure 1 Figure 1. Disclosures Ahmed: Xencor: Research Funding; Seagen: Research Funding; Tessa Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding. Flinn: Genentech: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Incyte: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Seagen: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Karyopharm Therapeutics: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; BeiGene: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Nurix Therapeutics: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Acerta Pharma: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Takeda: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Iksuda Therapeutics: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Agios: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; AstraZeneca: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Merck: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Verastem: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; MorphoSys: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Yingli Pharmaceuticals: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; AbbVie: Consultancy, Other: All Consultancy and Research Funding payments made to Sarah Cannon Research Institute, Research Funding; Juno Therapeutics: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Trillium Therapeutics: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Infinity Pharmaceuticals: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Forma Therapeutics: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Teva: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Gilead Sciences: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Novartis: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Pfizer: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; TG Therapeutics: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; ArQule: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; IGM Biosciences: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Loxo: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Kite, a Gilead Company: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Rhizen Pharmaceuticals: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Calithera Biosciences: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Portola Pharmaceuticals: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Roche: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Curis: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Forty Seven: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Celgene: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Unum Therapeutics: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Janssen: Consultancy, Other: All consultancy and research funding payments made to Sarah Cannon Research Institute, Research Funding; Constellation Pharmaceuticals: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Great Point Partners: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Triphase Research & Development Corp.: Other: All research funding payments made to Sarah Cannon Research Institute, Research Funding; Century Therapeutics: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Hutchison MediPharma: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Vincerx Pharma: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Sarah Cannon Research Institute: Current Employment; Servier Pharmaceuticals: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Yingli Pharmaceuticals: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Seagen: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Servier Pharmaceuticals: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute; Unum Therapeutics: Consultancy, Other: All consultancy payments made to Sarah Cannon Research Institute, Research Funding; Johnson & Johnson: Current holder of individual stocks in a privately-held company; Seattle Genetics: Research Funding. Mei: Epizyme: Research Funding; TG Therapeutics: Research Funding; BMS: Research Funding; GlaxoSmithKline: Honoraria; Morphosys: Honoraria; EUSA: Honoraria; Janssen: Honoraria. Riedell: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Calibr: Research Funding; Kite/Gilead: Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Research Funding; Tessa Therapeutics: Research Funding; MorphoSys: Research Funding. Armand: Infinity: Consultancy; Pfizer: Consultancy; Kite: Research Funding; Tensha: Research Funding; IGM: Research Funding; Genentech: Consultancy, Research Funding; Roche: Research Funding; Epizyme: Consultancy; AstraZeneca: Consultancy; Regeneron: Consultancy; Enterome: Consultancy; C4: Consultancy; GenMab: Consultancy; Miltenyi: Consultancy; Tessa Therapeutics: Consultancy; Daiichi Sankyo: Consultancy; Morphosys: Consultancy; Celgene: Consultancy; Otsuka: Research Funding; Sigma Tau: Research Funding; ADC Therapeutics: Consultancy; Adaptive: Consultancy, Research Funding; Affimed: Consultancy, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria, Research Funding. Grover: Novartis: Consultancy; ADC: Other: Advisory Board; Genentech: Research Funding; Kite: Other: Advisory Board; Tessa: Consultancy. Engert: Takeda: Consultancy, Honoraria, Research Funding; BMS: Honoraria, Research Funding; Astra Zeneca: Consultancy, Honoraria; Tessa Therapeutics: Consultancy; Hexal: Honoraria; ADC Therapeutics: Consultancy; Amgen: Honoraria; MSD: Honoraria. Lapteva: Tessa Therapeutics: Consultancy. Nadler: Tessa Therapeutics: Consultancy; Symphogen: Consultancy; Iksuda: Consultancy; Karyopharm: Consultancy. Myo: Tessa Therapeutics: Current Employment. Heslop: Novartis: Membership on an entity's Board of Directors or advisory committees; Kiadis: Membership on an entity's Board of Directors or advisory committees; Tessa Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Kuur Therapeutics: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Marker Therapeutics: Current equity holder in publicly-traded company; Allovir: Current equity holder in publicly-traded company; Gilead: Membership on an entity's Board of Directors or advisory committees; Fresh Wind Biotherapies: Membership on an entity's Board of Directors or advisory committees.
- Published
- 2021
29. PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group
- Author
-
Christian Baues, Bernd Hertenstein, Josée M. Zijlstra, Michael Fuchs, Annette Plütschow, Carsten Kobe, Max S. Topp, Marianne Just, Valdete Schaub, Richard Greil, Peter Borchmann, Andreas Engert, Thomas Pabst, Andreas Rosenwald, Helen Kaul, Dennis A. Eichenauer, Markus Dietlein, Anne Sophie Jacob, and Martin Vogelhuber
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,language.human_language ,German ,Internal medicine ,language ,medicine ,In patient ,Stage (cooking) ,business ,Favorable Hodgkin Lymphoma - Abstract
Background The primary analysis of the HD16 trial initiated in 2018 found that, in the treatment of early-stage favorable Hodgkin lymphoma (HL), involved-field radiotherapy (IF-RT) cannot be omitted from standard combined-modality treatment (CMT) without a clinically significant loss of tumor control. We thus complement the published analysis with prolonged follow-up and data on long-term toxicity. Methods Between 11/2009 and 12/2015, we enrolled 1150 patients aged 18-75 years with newly diagnosed HL in stages I or II without risk factors. Patients were randomized between standard CMT, with 2 cycles of ABVD followed by a centrally reviewed PET/CT-based restaging (PET-2) and 20 Gy IF-RT regardless of PET-2 result, and PET-2-guided treatment, with 2 cycles ABVD followed by 20 Gy IF-RT only in case of a positive PET-2 in terms of a Deauville score (DS) ≥3. Primary endpoint was PFS, analyzed according to Kaplan-Meier using Cox regression and log-rank test as applicable. We aimed at excluding inferiority of the PET-2-guided regimen in terms of a Hazard ratio (HR) of 3.01 or above in the PET-2-negative per-protocol cohort. Another aim was to assess the prognostic impact of PET-2 among those patients assigned to receive CMT. This follow-up analysis aims at repeating the main analyses with prolonged follow-up and complement efficacy results with long-term safety data. Findings With a median follow-up of 64 months, PET-2-negative patients had five-year PFS of 94.2% (95% CI 91.6-96.9) after CMT (n=328) and 86.7% (82.5-90.9) after ABVD alone in the PET-2-guided treatment group (n=300; HR 2.05 [1.20-3.51] including the non-inferiority margin; log-rank p=0.0072). The difference primarily resulted from recurrences that were at least in part located within the potential radiation field, with 5-year cumulative incidences of 2.0% (0.4-3.7) after CMT vs. 10.4% (6.7-14.1) after ABVD alone (p=0.0002). There was no difference regarding second primary malignancies, with 5-year cumulative incidences of 4.6% (2.1-7.1) after CMT vs. 4.2% (1.6-6.8) after ABVD (p=0.57). Five-year overall survival was 98.3% (96.9-99.8) and 98.8% (97.4-100), respectively (p=0.14), with 4 of the 12 documented deaths caused by second primary malignancies and only 1 by HL. Among patients assigned to receive CMT, PFS was superior in the PET-2-negative subgroup (DS 1-2) (n=353; 5-year PFS 94.0% [91.4-96.6]) compared with those having DS ≥3 (n=340; 90.3% [86.9-93.6]; p=0.012). The difference was more pronounced when the more commonly used cutoff of DS 4 was used for positivity (DS 1-3: n=571; 94.0% [91.9-96.0] vs. DS ≥4: n=122; 83.6% [76.6-90.6]; p After 5 years of follow-up, cardiac parameters showed normal outcomes in both randomized treatment groups and no relevant decrease compared with baseline values. Among 293 female patients aged 18-40 years at enrollment, the 5-year incidence of childbirth after therapy was 24.0% (15.9-32.2) after standard CMT vs. 17.9% (10.4-25.5) after PET-guided treatment. Conclusion We conclude that radiotherapy cannot be omitted from the treatment of early-stage favorable HL after a negative PET-2 without a clinically relevant and statistically significant loss of efficacy. We could not observe any disadvantage of standard CMT over PET-guided therapy in terms of acute or late toxicities. Overall survival is on a high level and not impaired by the omission of radiotherapy due to effective second-line therapies. Noteworthy the results of the HD16 trial became more pronounced with longer follow-up. This holds true for the per-protocol as well as for the intention-to-treat group. A positive PET after 2 cycles of ABVD in terms of DS ≥4 is associated with significantly inferior efficacy compared with a negative PET, indicating the need for further improvement in this group of patients. Taken together, we recommend that CMT is to be regarded as standard treatment for early-stage favorable HL. Disclosures Fuchs: BMS: Honoraria; Takeda: Consultancy, Honoraria; MSD: Honoraria; Celgene: Honoraria; Lukon: Honoraria. Greil: Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Daiichi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Sankyo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Sandoz: Honoraria, Research Funding. Topp: Amgen: Consultancy, Research Funding; Macrogeniecs: Research Funding; Regeneron: Consultancy, Research Funding; Gilead: Research Funding; Roche: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Universitatklinikum Wurzburg: Current Employment; Janssen: Consultancy; Celgene: Consultancy, Research Funding. Hertenstein: BMS: Honoraria; Celgene: Honoraria; Novartis: Honoraria; Sanofi: Honoraria. Zijlstra: Takeda: Research Funding. Engert: Astra Zeneca: Consultancy, Honoraria; ADC Therapeutics: Consultancy; Tessa Therapeutics: Consultancy; Hexal: Honoraria; MSD: Honoraria; Amgen: Honoraria; BMS: Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding.
- Published
- 2021
30. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis
- Author
-
William Krüger, Bernhard Heinrich, Martin Wilhelm, Vanja Zeremski, Norbert Grobe, Bastian von Tresckow, Peter Borchmann, Michael Fuchs, Jesko Momotow, Tobias Gaska, Burkhard Schmidt, Ina Bühnen, Andreas Hüttmann, Doris Kraemer, Paul J Bröckelmann, Gerhard Heil, Karolin Trautmann-Grill, Andreas Engert, Helmut Forstbauer, Guido Kobbe, and Kathleen Jentsch-Ulrich
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Medizin ,Cell Biology ,Hematology ,Biochemistry ,language.human_language ,German ,Internal medicine ,Relapsed refractory ,language ,Medicine ,Hodgkin lymphoma ,Center (algebra and category theory) ,business ,Anti pd1 - Abstract
Background: Immune-checkpoint inhibition with antibodies targeting programmed death protein 1 (PD1) was well tolerable and highly effective in pivotal phase II and III trials in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). We aimed to evaluate emerging therapeutic sequences and the safety and efficacy of anti-PD1 antibodies in the rapidly changing routine care of r/r cHL. Methods: GHSG-affiliated hemato-oncology departments and practices in Germany were invited to participate in this retrospective study. Patients ≥18 years of age receiving anti-PD1 antibodies for r/r cHL in routine care were eligible. Patient, disease and treatment characteristics were documented by the treating physicians with standardized case report forms. Locally assessed response rates were reported as complete (CR) or partial (PR) remission, stable (SD) or progressive (PD) disease and summarized as objective response rate (ORR: CR + PR). Progression-free (PFS) and overall survival (OS) were analyzed according to Kaplan-Meier from the start of anti-PD1 treatment in routine care to PD (PFS) or death from any cause (PFS + OS). All analyses were done descriptively and conducted in SAS V9.4. Results: A total of 58 r/r cHL patients (pts.) with a median age of 48 years (range 19-89 years) and male predominance (57%) initiated anti-PD1 treatment between 11/2014 and 01/2021 at 15 sites. Median time from 1 st-line to anti-PD1 treatment was 5.5 years (0.8-26.0). The majority had received prior brentuximab vedotin (BV, 86%) or an autologous stem-cell transplantation (autoSCT, 62%) and 16% undergone prior alloSCT. Relevant co-morbidities including HIV, pre-existing autoimmune conditions, cardiovascular diseases and dialysis-dependent kidney failure were documented in 49% of patients. An impaired ECOG performance status of ≥1 was present in 57% of patients (ECOG 2: 12%, ECOG 3: 4%). At initiation of anti-PD1 treatment, 74% of patients presented with stage III/IV disease and 35% did not achieve a response to their latest prior therapy. The median duration of anti-PD1 treatment was 18.1 (0.5-79.3) months and 50% of patients still received an anti-PD1 antibody at data collection. One third (31.6%) of patients experienced grade III/IV treatment-related toxicities and a treatment delay of >6 weeks due to toxicity occurred in 15.5% of patients. Investigator-assessed ORR was 66.7% with 20.4% of patients achieving a CR and 46.3% a PR as best response (Figure 1A). With a median follow-up of 19.1 (0-74.7) months and 26.7 (0-74.7) for PFS and OS, respectively, median PFS (mPFS) and OS were 12.3 months and 32 months, respectively (Figure 1B+C). Corresponding 2-year PFS and OS estimates were 38.3% (95%CI 24.4-52.2) and 78.5% (95%CI 67.2-89.8). Median PFS was more favorable in patients achieving either a CR (30.1 months) or PR (24.9 months) compared to SD (9.3) or PD (3.4, Figure 1D), with similar trends also observed for OS. Two thirds (67%) of the 29 patients eventually experiencing PD, continued anti-PD1 treatment beyond progression at least once, with a median duration of 9.9 (3.0-25.8) until 2 nd PD. Overall, 28% patients received concomitant add-on treatments with radiotherapy (62.5%) and chemotherapy (25%) administered simultaneously most commonly. Best response to combination treatment was PR in 84.6% and SD in 15.4% of patients, and 75% of patients receiving add-on treatments achieved their best response only thereafter. Most common consecutive treatments were allogeneic stem-cell transplantation (N=5), BV-based therapy (N=5), Gemcitabine-based regimens (N=4) radiotherapy (N=4) and N=13 patients did not receive further treatment after anti-PD1 failure. Most common cause of death was cHL (58% of deaths reported), followed by non-anti-PD1 treatment-related causes (16%), infections and cardiac diseases (11% each) and second neoplasms (5%). Conclusions: In this multicenter cohort of older and frailer r/r cHL patients receiving anti-PD1 antibodies in routine care, safety and efficacy data including ORR, mPFS and mOS was similar to data reported from pivotal phase II trials. Anti-PD1 treatment for r/r cHL thereby appears feasible and able to induce meaningful clinical benefit in a broad range of patients. Despite various concomitant and subsequent treatments administered, however, cHL or subsequent treatments are by far the leading cause of death. Failure of anti-PD1 in r/r cHL hence constitutes an unmet need. Figure 1 Figure 1. Disclosures Trautmann-Grill: GSK: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Kobbe: Celgene: Research Funding. Heinrich: Roche: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Eisai: Consultancy; Lilly: Consultancy, Research Funding; Sanofi: Consultancy; Astra: Consultancy, Research Funding; Abbvie: Research Funding. Schmidt: Incyte: Honoraria; Biotest: Honoraria; Alexion: Honoraria; AbbVie: Honoraria; Sanofi-Aventis: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Janssen: Honoraria. Hüttmann: Celgene: Honoraria; Gilead: Honoraria; Lead Discovery Center GmbH: Consultancy; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Fuchs: Lukon: Honoraria; Celgene: Honoraria; MSD: Honoraria; BMS: Honoraria; Takeda: Consultancy, Honoraria. von Tresckow: Novartis: Consultancy, Honoraria, Other: congress and travel support, Research Funding; Kite-Gilead: Consultancy, Honoraria; MSD: Consultancy, Honoraria, Other: congress and travel support, Research Funding; Takeda: Consultancy, Honoraria, Other, Research Funding; Roche: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Pentixafarm: Consultancy, Honoraria; BMS-Celgene: Consultancy, Honoraria, Other: congress and travel support; AstraZeneca: Honoraria, Other: congress and travel support; Amgen: Consultancy, Honoraria; AbbVie: Other: congress and travel support. Borchmann: Gilead Sciences: Honoraria; BMS/Celgene: Honoraria; Janssen: Honoraria; Miltenyi Biotech: Honoraria; Novartis: Honoraria. Engert: MSD: Honoraria; Hexal: Honoraria; BMS: Honoraria, Research Funding; Astra Zeneca: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Tessa Therapeutics: Consultancy; Amgen: Honoraria; ADC Therapeutics: Consultancy. Bröckelmann: BMS: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; MSD: Research Funding; BeiGene: Research Funding.
- Published
- 2021
31. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
- Author
-
Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional
- Published
- 2020
- Full Text
- View/download PDF
32. Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
- Author
-
Antic, Darko, primary, Otasevic, Vladimir, additional, Borchmann, Sven, additional, Muller, Horst, additional, Vukovic, Vojin, additional, Djurasinovic, Vladislava, additional, Tomic, Kristina, additional, Mihaljevic, Biljana, additional, Gerotziafas, Grigoris, additional, Engert, Andreas, additional, and Fareed, Jawed, additional
- Published
- 2020
- Full Text
- View/download PDF
33. AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
- Author
-
Sasse, Stephanie, primary, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional
- Published
- 2020
- Full Text
- View/download PDF
34. Influence of antigen on the development of MALT lymphoma
- Author
-
Lenze, Dido, Berg, Erika, Volkmer-Engert, Rudolf, Weiser, Armin A., Greiner, Axel, Knörr-Wittmann, Constanze, Anagnostopoulos, Ioannis, Stein, Harald, and Hummel, Michael
- Published
- 2006
- Full Text
- View/download PDF
35. AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
- Author
-
Nadezda Basara, Carsten Kobe, Peter Borchmann, Andreas Engert, Jesko Momotow, Sven Thorspecken, Bastian von Tresckow, Christian Koenecke, Annette Plütschow, Michael Fuchs, Markus Dietlein, Andreas Hüttmann, Sonja Martin, Martin Bentz, Maike de Wit, Christina Grosse-Thie, and Stephanie Sasse
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Medizin ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Loading dose ,Internal medicine ,Refractory Hodgkin Lymphoma ,Clinical endpoint ,Medicine ,In patient ,Progression-free survival ,Open label ,business ,Brentuximab vedotin ,Progressive disease ,medicine.drug - Abstract
INTRODUCTION: The outcome of patients (pts) with classical Hodgkin Lymphoma (cHL) experiencing relapse after high dose chemotherapy, brentuximab vedotin (BV) and anti-PD1 antibody (Ab) treatment is poor and in most patients the duration of the response to this treatment is rather short. Thus, there still is a need for new treatment options. A promising immunotherapeutic approach is the bispecific anti-CD30/CD16A antibody AFM13. METHODS: Pts ≥ 18 years with relapsed or refractory cHL after standard therapy including BV and anti-PD1 Ab were included in this two-stage trial (NCT02321592). In stage I pts were initially assigned in a 1:1 ratio to either Arm A with 1.5 mg/kg AFM13 3x/ week for 8 weeks or Arm B with 1.5 mg/kg AFM13 3x/ week for 2 weeks followed by 1 infusion of 7.0 mg/kg/week for 6 weeks. After an amendment to this trial, all further pts received 7 mg/kg per week, with 1 mg/kg loading dose and 6 mg/kg as continuous infusion for 5 days/ week thereafter (Arm C). If ≥ 2 overall responders were observed in 10 pts, the respective trial arm qualified for stage 2. Primary endpoint was the objective response (complete/partial remission (CR/PR)) after the first cycle. Secondary endpoints included efficacy (Overall survival (OS), Progression free survival (PFS)) and safety analyses. RESULTS: Between June 26, 2015 and May 31, 2019, 25 pts were assigned to arm A (n=5), B (n=12), or C (n=8), respectively, and qualified for statistical analyses. Median age of the study population was 45 (range 21-73) years. 24/25 patients were male. Clinical stages 2, 3 and 4 were diagnosed in 8 (32%), 9 (36%), and 8 (32%) patients, respectively. Patients had received a median of 3 (range 1-11) salvage-therapy lines after first-line therapy. Since the trial was terminated in stage I due to a lack of recruitment, all statistical analyses of primary and secondary endpoints are also of descriptive nature. The central response evaluation panel included 24 of 25 pts: The objective response rate was 16.6% including 1 complete response (CR) and 3 partial responses (PR). Stable disease (SD) was documented in 6 pts and progressive disease (PD) in 14 pts. The responses were distributed as follows to the treatment arms: Two responses were documented in arm C and one response was documented in arm A and B, respectively. Second cycle AFM13 was started in 5 patients. Two patients had PD during or after cycle 2, and one patient each was diagnosed with CR, PR, or SD. During follow-up, there were 22 cases of PD and 9 deaths. With a median observation time for PFS of 5.5 months (95% CI 2.6 - 11.0), the 12-months PFS estimate was 12.6% (95%-CI 3.2 - 28.9) (Fig.1). With a median observation time of 14.5 months (95% CI 12.9-16.8) the 12-months OS estimate was 62% (95% CI 39.6-78.1). In only 5/25 pts serious adverse events due to hospitalization were observed; two events were characterized as serious adverse reaction: one CTC grade 4 and one CTC grade 2 infusion related reaction. All events resolved completely. CONCLUSION: Treatment with AFM13 was well tolerated and showed modest activity in heavily pretreated pts. The responses documented in arm C qualified this arm with continuous AFM13 application over 5 days for further evaluation in trial stage 2 and thus indicated its potential. However, the trial was prematurely stopped due to low recruitment leading to the conclusion that the acceptance of the application schedule is extremely important. Disclosures Hüttmann: Roche: Other: Travel expenses; Seattle Genetics: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Gilead: Honoraria; Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Lead Discovery Center GmbH: Consultancy; University Hospital Essen, University of Duisburg-Essen, Essen, Germany: Current Employment. Grosse-Thie:Abbvie: Other: Travel Grants; Bristol-Myers Squibb: Honoraria, Other: Travel Grants; Amgen: Honoraria; Novartis: Honoraria; Daiichi Sankyō: Other: Travel Grants. von Tresckow:Kite/Gilead: Honoraria; Pfizer: Honoraria; Amgen: Honoraria; Takeda: Honoraria, Other: Travel support, Research Funding; Novartis: Other: Travel support, Research Funding; Takeda: Honoraria, Other: Travel support, Research Funding; MSD Sharp & Dohme: Honoraria, Research Funding; Roche: Honoraria. Fuchs:Takeda: Honoraria; Celgene: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Affimed: Honoraria. Borchmann:Takeda: Research Funding; Bristol Myers Squibb: Research Funding. Engert:Takeda: Honoraria, Research Funding; MSD Sharp & Dohme: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Affimed Therapeutics: Research Funding; AstraZeneca: Honoraria; Sandoz: Honoraria.
- Published
- 2020
36. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
- Author
-
Carsten Kobe, Paul J Bröckelmann, Wolfram Klapper, Peter Borchmann, Andreas Rosenwald, Andreas Hüttmann, Ulrich Keller, Christian Baues, Stephan Mathas, Bastian von Tresckow, Karolin Trautmann, Julia Meissner, Michael Fuchs, Martin Sökler, Matthias Bormann, Stephanie Sasse, Andreas Zimmermann, Andrea Kerkhoff, Andreas Engert, Teresa V Halbsguth, and Helen Goergen
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Immunology ,medicine ,Cell Biology ,Hematology ,Nivolumab ,Stage (cooking) ,business ,Biochemistry ,Unfavorable Hodgkin Lymphoma - Abstract
Background The primary analysis of the investigator-sponsored randomized multicenter phase II GHSG NIVAHL trial showed feasibility and excellent short-term efficacy of anti-PD1 based 1st-line treatment of early-stage unfavorable classical Hodgkin lymphoma (cHL). Achieving long-term disease control without excessive treatment-related morbidity is of utmost importance when developing innovative 1st-line cHL therapies. Duration of response and development of persisting immune-related toxicities are of concern in the setting of 1st-line anti-PD1 treatment. Methods NIVAHL enrolled treatment naïve early-stage unfavorable cHL patients at 28 German centers and individuals were randomized to either receive fully concomitant 4x Nivo-AVD (group A) or sequential 4xnivolumab, followed by 2x Nivo-AVD and 2x AVD (group B). Both groups received consolidative 30Gy IS-RT and the primary endpoint was complete response (CR) rate at end of study treatment. Detailed methods, patient characteristics and the primary endpoint analysis of NIVAHL have been recently published (Bröckelmann PJ et al. JAMA Oncol 2020). Herein we present extended follow-up of the NIVAHL trial to assess efficacy in terms of 2-year progression-free (PFS) and overall survival (OS) as well as safety with regards to long-term toxicities or organ impairment documented during the first year of follow-up after treatment. Results A total of 109 patients with cHL confirmed by central pathology review were enrolled between 04/2017 - 10/2018 and followed for a median of 20 and 21 months in groups A (n=55) and B (n=54), respectively, for the present analysis. All of the 7 patients deemed in partial remission (PR) at end of study treatment (EOT) converted into an ongoing CR after end of study without additional treatment during follow-up. With no relapse and no death observed since the primary analysis, the 2-year PFS estimates are 100% and 98% (95%CI 88-100%) in groups A and B, respectively, and the 2-year OS is 100% in both groups. With a median observation time for late-toxicities of 14 months after EOT (range 6-26 months) among 103 patients, any potentially treatment-related AE during follow-up was reported in 65% of patients (A: 74%, B: 56%). The highest documented CTCAE grade of late AEs was °I in 33%, °II in 25% and °III in 7% of patients with no °IV-V AEs observed. A total of 54% had at least one late event related to AVD, 47% to nivolumab and 32% to RT, with multiple relations attributable per event. Mean FEV1 and DLCOc did not decrease from baseline (91.1% -> 96.4% and 86.2% -> 83.3%, respectively). Decreased LVEF after EOT was reported in 2/56 patients with available data (4%). After EOT, 18% of patients required medication for adverse events. Corticosteroid ≥ and < 10mg prednisolone equivalent was required in 3% and 2% of patients, respectively, for a toxicity at any time during follow-up. No patient required corticosteroid treatment at last available follow-up. Most frequent toxicities reported after EOT included fatigue (21%), hypothyroidism (17%), respiratory tract disorders (16%), leukopenia (14%) and nervous system disorders (14%). Hypothyroidism was the event most frequently solely attributed to nivolumab during follow-up. The median time to onset after EOT was 5 months and affected patients nearly exclusively female (15/16 [94%]). After median follow-up of 10 months (range 0-21), hypothyroidism remained unchanged in 10 of 16 affected patients and resolved in 3 patients. Conclusion The excellent disease control of concomitant and sequential nivolumab and AVD in early-stage unfavorable cHL is confirmed with the currently available follow-up. Treatment-related toxicities ongoing or emerging during follow-up are predominantly associated with chemo- and/or RT. The most frequent nivolumab-associated late toxicity is hypothyroidism. No patient currently requires chronic corticosteroid treatment. Disclosures Bröckelmann: Bristol Myers Squibb: Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; MSD Sharp & Dohme: Research Funding. Keller:Bristol Myers Squibb: Honoraria, Other: Travel support, Speakers Bureau. Meissner:Celgene: Other: Travel support; Bristol Myers Squibb: Other: Travel support; Takeda: Other: Travel support; Merck Sharp & Dohme: Other: Travel support; Hexal: Other: Travel support. Trautmann:Bristol Myers Squibb: Honoraria. Kerkhoff:BMS: Honoraria. Hüttmann:Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Lead Discovery Center GmbH: Consultancy; Seattle Genetics: Research Funding; Gilead: Honoraria; University Hospital Essen, University of Duisburg-Essen, Essen, Germany: Current Employment; Roche: Other: Travel expenses; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). Zimmermann:Takeda: Consultancy, Honoraria, Other: Travel Expenses; Bristol-Myers Squibb: Other: Travel Expenses; MSD: Other: Travel Expenses; Novartis: Other: Travel Expenses. Fuchs:Bristol Myers Squibb: Honoraria, Research Funding; Affimed: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Celgene: Honoraria. von Tresckow:Takeda: Honoraria, Other: Travel support, Research Funding; Novartis: Other: Travel support, Research Funding; Takeda: Honoraria, Other: Travel support, Research Funding; MSD Sharp & Dohme: Honoraria, Research Funding; Roche: Honoraria; Kite/Gilead: Honoraria; Pfizer: Honoraria; Amgen: Honoraria. Borchmann:Takeda: Research Funding; Bristol Myers Squibb: Research Funding. Engert:Bristol Myers Squibb: Honoraria, Research Funding; Affimed Therapeutics: Research Funding; Takeda: Honoraria, Research Funding; MSD Sharp & Dohme: Honoraria; AstraZeneca: Honoraria; Sandoz: Honoraria. OffLabel Disclosure: Nivolumab 240mg Q2W alone or in combination with AVD for 1st-line treatment of classical Hodgkin lymphoma.
- Published
- 2020
37. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
- Author
-
Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary
- Published
- 2019
- Full Text
- View/download PDF
38. Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial
- Author
-
Bröckelmann, Paul J, primary, Plütschow, Annette, additional, Greil, Richard, additional, Zijlstra, Josée M, additional, Illidge, Timothy, additional, Fosså, Alexander, additional, Meissner, Julia, additional, Zimmermann, Andreas, additional, Mathas, Stephan, additional, Thol, Felicitas, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Baues, Christian, additional
- Published
- 2019
- Full Text
- View/download PDF
39. Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial
- Author
-
Voltin, Conrad-Amadeus, primary, Mettler, Jasmin, additional, Mueller, Horst, additional, Fuchs, Michael, additional, Baues, Christian, additional, Dietlein, Markus, additional, Engert, Andreas, additional, Borchmann, Peter, additional, Kobe, Carsten, additional, and Bröckelmann, Paul J, additional
- Published
- 2019
- Full Text
- View/download PDF
40. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial
- Author
-
Gillessen, Sarah, primary, Plütschow, Annette, primary, Fuchs, Michael, primary, Markova, Jana, primary, Greil, Richard, primary, Topp, Max S., primary, Meissner, Julia, primary, Zijlstra, Josée M, primary, Eichenauer, Dennis A., primary, Diehl, Volker, primary, Borchmann, Peter, primary, Engert, Andreas, primary, and von Tresckow, Bastian, primary
- Published
- 2019
- Full Text
- View/download PDF
41. Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
- Author
-
Vojin Vukovic, Horst Müller, Jawed Fareed, Darko Antic, Biljana Mihaljevic, Grigoris T. Gerotziafas, Sven Borchmann, Kristina Tomic, Vladimir Otasevic, Vladislava Djurasinovic, and Andreas Engert
- Subjects
0303 health sciences ,medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Thromboembolic complication ,medicine ,Hodgkin lymphoma ,Radiology ,business ,030304 developmental biology ,030215 immunology - Abstract
INTRODUCTION: Thromboembolism (TE) in lymphoma patients is gathering substantial attention due to its impact on morbidity and mortality of those patients. The association between lymphoma and increased risk for TE development, especially venous thromboembolism (VTE), has lately been well established through numerous publications. Thrombosis Lymphoma (ThroLy) score has been initially developed as a simple risk assessment model for the risk of TE development in lymphoma patients. It has been both internally and externally validated in several studies, which dominantly included patients with non-Hodgkin lymphoma (NHL). Therefore, aim of our study is to analyse and validate ThroLy score in an extensive cohort of Hodgkin lymphoma (HL) patients. METHODS: A total of 5509 newly diagnosed HL patients, from the German Hodgkin Study Group (GHSG) HD13-15 trials, were included in this study. Data has been obtained for all venous and arterial TE events in HL patients from time of diagnosis to 3 months after the last cycle of therapy. TE was diagnosed objectively based on radiographic studies (duplex venous ultrasound, contrast-enhanced thoracic computed tomography scan, magnetic resonance imaging (MRI) - for central nervous system (CNS) thrombosis, or angiograms (for arterial thrombosis), clinical examination and laboratory evaluation. Based on ThroLy score, patients were divided in three risk categories: low (score 0-1), intermediate (score 2-3) and high risk (score >3). Patients with intermediate and high-risk score were classified at risk. The validation was conducted through Chi-square test, ROC analysis and logistic regression. RESULTS: The mean patients' age was 35.9 years (range, 18-75 years); 55.7% were males. The majority of patients had limited or intermediate stage of disease: Ann Arbor stage I 10.6%, and stage II 57.5%. 190 (3.4%) patients developed thromboembolic events, 173 patients with VTE (3.14%), and 17 with arterial TE (0.31%), respectively. Chi-square test showed statistically significant association between TE and ThroLy score, both in three risk groups (chi-square = 18.236, p≤0.001) and two risk groups: low and at risk (chi-square = 18.029, p≤0.001). The sensitivity, specificity, negative and positive predictive value were 49%, 65%, 95%, and 97%, respectively. Binary logistic regression of ThroLy score showed statistically significant performance in prediction of TE events in HL patients, with satisfactory validity indicators (Ombinus Test chi-square = 11.668, p=0.001; AIC=44.956, BIC = 97.869). Diagnostic accuracy of ThroLy score was calculated via ROC curve (area under curve (AUC)=0.57). CONCLUSION: ThroLy score demonstrated its capability of risk prediction for TE events in HL patients. The limited statistical performance of the ThroLy score requires further research towards possible score enhancement. Disclosures Engert: AstraZeneca: Honoraria; MSD Sharp & Dohme: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Affimed Therapeutics: Research Funding; Sandoz: Honoraria; Takeda: Honoraria, Research Funding.
- Published
- 2020
42. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- Author
-
Dirk Huebner, Emily K. Larsen, Scott E. Smith, Joseph D. Rosenblatt, Stephen M. Ansell, Joseph M. Connors, Ajay K. Gopal, Anas Younes, Kerry J. Savage, Robert T. Chen, Abraham P. Fong, and Andreas Engert
- Subjects
Adult ,Male ,medicine.medical_specialty ,Immunoconjugates ,Immunology ,Salvage therapy ,Biochemistry ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,Refractory ,Internal medicine ,Refractory Hodgkin Lymphoma ,medicine ,Humans ,Brentuximab vedotin ,Survival rate ,Neoplasm Staging ,Brentuximab Vedotin ,Salvage Therapy ,business.industry ,Remission Induction ,Cell Biology ,Hematology ,Prognosis ,medicine.disease ,Hodgkin Disease ,Confidence interval ,Surgery ,Survival Rate ,Peripheral neuropathy ,030220 oncology & carcinogenesis ,Female ,Neoplasm Recurrence, Local ,business ,030215 immunology ,medicine.drug - Abstract
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.
- Published
- 2016
43. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
- Author
-
Borchmann, Peter, Treml, John F., Hansen, Hinrich, Gottstein, Claudia, Schnell, Roland, Staak, Oliver, Zhang, Hui-fen, Davis, Thomas, Keler, Tibor, Diehl, Volker, Graziano, Robert F., and Engert, Andreas
- Published
- 2003
- Full Text
- View/download PDF
44. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
- Author
-
Andrea Kerkhoff, Peter Borchmann, Bastian von Tresckow, Felicitas Hitz, Paul J Bröckelmann, Karolin Behringer, Richard Greil, Sven Borchmann, Carolin Bürkle, Andreas Engert, Helen Goergen, Michael Fuchs, Dennis A. Eichenauer, Volker Diehl, and Boris Böll
- Subjects
Adult ,Lung Diseases ,Male ,medicine.medical_specialty ,Pulmonary toxicity ,Dacarbazine ,medicine.medical_treatment ,Immunology ,Kaplan-Meier Estimate ,Vinblastine ,Bleomycin ,Biochemistry ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Adverse effect ,Aged ,Neoplasm Staging ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Remission Induction ,Age Factors ,Cell Biology ,Hematology ,Middle Aged ,Hodgkin Disease ,Chemotherapy regimen ,Surgery ,chemistry ,ABVD ,Doxorubicin ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology ,medicine.drug - Abstract
Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). Therefore, using bleomycin has been questioned in older Hodgkin lymphoma (HL) patients, especially in early-stage HL. We therefore analyzed feasibility, toxicity, and efficacy of ABVD or AVD in 287 older early-stage favorable HL patients. We included patients ≥60 years of age in the German Hodgkin Study Group HD10 and HD13 trials randomized to either 2 cycles of ABVD (2×ABVD; n = 137) or AVD (2×AVD; n = 82), each followed by involved-field radiotherapy (IF-RT), with patients randomized to 4×ABVD+IF-RT (n = 68). Patients' median age was 65 years (range, 60-75) with comparable patient and disease characteristics. Grade III-IV adverse event rates were similar in patients receiving 2×AVD and 2×ABVD (40% and 39%, respectively), but considerably higher in patients receiving 4×ABVD (65%). Similarly, BLT was rare in patients receiving 2×ABVD/AVD, but occurred in 7/69 (10%) of patients randomized to 4×ABVD, with 3 lethal events. In conclusion, no effects of bleomycin on toxicity rates were detectable in older patients receiving 2 cycles of chemotherapy. However, we found a high risk of severe toxicity of bleomycin in older HL patients receiving more than 2 cycles of ABVD. These trials are registered at www.clinicaltrials.gov and www.isrctn.com as #NCT00265018 (HD10) and #ISRCTN63474366 (HD13).
- Published
- 2016
45. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
- Author
-
Rehwald, Ute, Schulz, Holger, Reiser, Marcel, Sieber, Markus, Staak, Jan Oliver, Morschhauser, Franck, Driessen, Christoph, Rüdiger, Thomas, Müller-Hermelink, Konrad, Diehl, Volker, and Engert, Andreas
- Published
- 2003
- Full Text
- View/download PDF
46. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial
- Author
-
Julia Meissner, Jana Markova, Josée M. Zijlstra, Annette Plütschow, Andreas Engert, Max S. Topp, Peter Borchmann, Richard Greil, Volker Diehl, Dennis A. Eichenauer, Bastian von Tresckow, Michael Fuchs, and Sarah Gillessen
- Subjects
medicine.medical_specialty ,Long term follow up ,business.industry ,Immunology ,Cell Biology ,Hematology ,Interim analysis ,Biochemistry ,Cancer recurrence ,Treatment failure ,Regimen ,Internal medicine ,medicine ,Clinical endpoint ,Early Unfavorable Hodgkin Lymphoma ,Dose intensification ,business - Abstract
Background: In early unfavorable Hodgkin Lymphoma (HL), long-term tumor control with 4xABVD and 30Gy involved field radiotherapy (IFRT) is approximately 80%. To improve these results, the GHSG HD14 trial compared an intensified chemotherapy regimen consisting of 2xBEACOPPescalated plus 2xABVD (2+2) to 4xABVD. All patients received 30Gy IFRT. Due to a progression-free survival (PFS) difference of 6.2% at five years in favor of the intensified treatment, 2+2 plus 30Gy RT is the current GHSG standard and is a treatment option in the NCCN guidelines for early unfavorable HL. However, there was no overall survival (OS) difference between 2+2 and 4xABVD at the final analysis of HD14 and the potential long-term toxicity of 2+2 is debated. We therefore performed a long-term follow up analysis of HD14. Patients and Methods: Between January 2003 and July 2008, 1,550 patients with early unfavorable HL ≤60 years were randomized and treated with 4xABVD or 2+2, followed by 30Gy IFRT in all patients. Randomization was discontinued after the third planned interim analysis showed a significant advantage of 2+2 in terms of the primary endpoint freedom from treatment failure (FFTF, difference 7.2% at 5 years). Accrual to the 2+2 arm continued from July 2008 to December 2009 and 339 additional qualified patients were treated with 2+2 plus 30Gy IFRT. These patients were not reported in the initial report and are added to all analyses of this long-term follow-up. Time-to-event end points were compared between groups using the Kaplan-Meier method as well as univariate and multivariate Cox regression models. Results: After a median observation time of 97 months, 10.2% (79 of 777) and 3.4% (38 of 1112) of patients treated with 4xABVD and 2+2, respectively, had progression or relapse. The 10-year PFS was 85.6% for 4xABVD (95%-CI 82.9% to 88.4%) and 91.2% for 2+2 (95%-CI 89.0% to 93.4%) accounting for a significant PFS difference of 5.6% (95%-CI 2.1% to 9.1%) in favor of 2+2 (Figure 1). Two or more relapses were experienced by 21 of 777 (2.7%) and 10 of 1112 (0.9%) patients who had received 4xABVD or 2+2 as first-line treatment, respectively. However, there was still no OS difference between the two groups (OS 94.1% [95%-CI 92.3% to 96%] and 94% [95%-CI 92.3% to 95.8%] for 4xABVD and 2+2, respectively; difference at 10 years -0.1% [95%-CI -2.6% to 2.4%], median observation time for OS 104 months). In a multivariate regression analysis adjusting for age, B-symptoms, infra-diaphragmatic disease, and the 4 GHSG risk factors (elevated ESR, involvement of ≥3 lymph node areas, extranodal disease, and large mediastinal tumor) as predictive factors for PFS, age ≥50 (HR 2.260, 95%-CI 1.543 to 3.309), presence of infra-diaphragmatic disease (HR 1.766, 95%-CI 1.055 to 2.955), or of a large mediastinal tumor (HR 1.811, 95%-CI 1.226 to 2.675) and treatment with 4xABVD (HR 1.929, 95%-CI 1.423 to 2.614) were significant predictors of PFS. Slightly more patients in the 4xABVD group died from toxicity of salvage therapy as compared to 2+2 patients (1% [8 of 777] versus 0.6% [7 of 1112]) whereas there were relatively more deaths due to study therapy in the 2+2 group as compared to 4xABVD patients (0.6% [7 of 1112] versus 0.1% [1 of 777]), leading to a similar OS in both groups. There were no apparent differences in other causes of death including HL (5 of 777 [0.6%] versus 9 of 1112 [0.8%]) and second neoplasms (12 of 777 [1.5%] versus 16 of 1112 [1.4%]) between 4xABVD and 2+2, respectively. A total of 95 second malignancies corresponding to 10-year cumulative second malignancy incidences of 4.7% and 6.4% were reported for 4xABVD and 2+2, respectively, without a difference between the two groups (p=0.86). Standardized incidence ratios (SIR) showed elevation compared to the general German population and no significant difference between 4xABVD (2.3 [95%-CI 1.6 to 3.2]) and 2+2 (2.6 [95%-CI 2.0 to 3.4]). Conclusions: This long-term analysis confirms the superior tumor control of 2+2 as compared to 4xABVD in patients ≤60 with early unfavorable HL. However, this does not translate into an OS difference. At longer follow-up, there is no difference regarding second primary malignancies between the groups. In comparison to 4xABVD, the 2+2 regimen spares a significant number of patients from the burden of cancer recurrence and additional treatment without increased long-term toxicity. Therefore, 2+2 remains the GHSG standard for patients with early unfavorable HL ≤60. Disclosures Greil: Novartis: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; GSK: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Ratiopharm: Research Funding; Roche: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Eisai: Honoraria; Boehringer Ingelheim: Honoraria; Pfizer: Honoraria, Research Funding; Mundipharma: Honoraria, Research Funding; MSD: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Amgen: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Sandoz: Honoraria; Janssen-Cilag: Honoraria; Genentech: Honoraria, Research Funding; Sanofi Aventis: Honoraria; Celgene: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Merck: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding. Topp:Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Regeneron Pharmaceuticals, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Zijlstra:Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria. Borchmann:Novartis: Honoraria, Research Funding. von Tresckow:Takeda: Consultancy, Honoraria, Other: Travel and congress funding, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel and congress funding, Research Funding; Pfizer: Honoraria; Amgen: Honoraria; Roche: Honoraria; MSD: Consultancy, Honoraria, Other: Travel and congress funding, Research Funding.
- Published
- 2019
47. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
- Author
-
Stephan Mathas, Carsten Kobe, Julia Meissner, Andreas Zimmermann, Andreas Hüttmann, Peter Borchmann, Christian Baues, Paul J Bröckelmann, Andreas Rosenwald, Helen Goergen, Andrea Kerkhoff, Matthias Bormann, Wolfram Klapper, Rainer Ordemann, Andreas Engert, Teresa V Halbsguth, Bastian von Tresckow, Michael Fuchs, Stephanie Sasse, Martin Sökler, and Ulrich Keller
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Surrogate endpoint ,business.industry ,Dacarbazine ,Immunology ,Medizin ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Discontinuation ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Chemoimmunotherapy ,Internal medicine ,Concomitant ,medicine ,Clinical endpoint ,Nivolumab ,business ,Progressive disease ,030215 immunology ,medicine.drug - Abstract
Background The anti-PD1 antibody nivolumab is approved for relapsed or refractory classical Hodgkin lymphoma (cHL) showing high overall response rates (ORR) and a favorable safety profile. However, complete response (CR) is rare in this setting, and most patients develop progressive disease. To evaluate the efficacy of combined nivolumab and doxorubicin, vinblastine and dacarbazine (AVD) as 1st-line treatment for early-stage unfavorable cHL, we conducted the GHSG NIVAHL trial. Methods NIVAHL is a prospective, randomized, investigator-sponsored single-stage phase II trial that enrolled treatment-naïve early-stage unfavorable cHL patients between 18 and 60 years at 35 German centers (NCT03004833). In arm A, patients received 240mg nivolumab and AVD at standard doses on day 1 and 15 of each 28-day cycle for a total of four cycles (4xNivoAVD). In arm B, the same treatment was administered sequentially, starting with 4x nivolumab in 2-weekly intervals, followed by 2xNivoAVD and 2xAVD. Both groups received 30Gy involved-site radiotherapy (IS-RT). Primary endpoint is the centrally reviewed PET/CT-based CR rate after completion of protocol therapy including IS-RT. 55 patients per group were enrolled in order to exclude a CR rate ≤80% with a power of 90% on a one-sided alpha level of 2.5% each. Secondary endpoints will be analyzed descriptively and include treatment-related morbidity (TRMorbidity), progression-free (PFS), overall survival (OS), response at interim and final restaging as well as patient-reported outcomes. Sequential biopsies, blood and microbiome samples were collected for correlative studies. Results Between 04/2017 and 10/2018, a total of 110 patients were enrolled with one patient disqualified due to alteration of HL diagnosis by central pathology review (N=109, group A n=55, group B n=54). The median age of the predominantly female patients (60%) was 27 years. Stage II was present in 95% of cases with ≥3 involved areas as most common risk factor (69%), followed by elevated ESR (48%), large mediastinal mass (20%) and extranodal disease (13%). Mean duration of chemoimmunotherapy was 15 (standard deviation (SD) 3) weeks and 22 (SD 6) weeks with a mean relative dose intensity of 87.4 (SD 15.9)% and 85.8 (SD 24.2)% in groups A and B, respectively. Severe protocol deviations occurred in 4 patients in group A and 5 in group B. Reasons were toxicity (n=5), patient's wish (n=2), incorrect allocation to early-stage unfavorable risk group (n=1) and progressive disease (n=1). Another 2 patients refused to receive IS-RT. Any adverse events (AEs) were reported for 98% of patients. AEs ≥°3 were observed in 73% and 78%, respectively, and serious AEs occurred in 38% and 28% of patients in groups A and B, respectively. TRMorbidity defined as organ toxicity ≥°3 or anemia, thrombocytopenia or infection °4 was documented in 16% and 22% of patients; all of these were organ toxicities predominantly of liver and gastrointestinal tract, with 19/21 events occurring during the first 2 treatment cycles. Data on ongoing or late toxicities is limited by short follow-up. Until 07/2019, 4 cases of persistent hypothyroidism have been reported. At the 1st interim restaging after 2xNivoAVD and 4x nivolumab, the ORR was 100% (54/54) and 96% (49/51), with a CR rate of 85% and 53% in groups A and B, respectively. Interim remission status was not assessed in 1 and 3 patients, respectively, due to treatment discontinuation after incorrect allocation to early-stage unfavorable risk group (n=1) or toxicity (n=3). After completion of systemic therapy, ORR was 100% (54/54) and 98% (50/51) with a CR rate of 81% and 86%, respectively. One patient in group B developed histologically proven primary progressive HL during nivolumab monotherapy while no other case of progressive or relapsed disease or death has been documented so far. The centrally reviewed CR rate at the end of treatment will be reported at the meeting. Additionally, initial data from currently ongoing histopathologic and immunologic studies will also be presented. Conclusion Concomitant and sequential therapy with nivolumab and AVD is feasible with acceptable toxicity. In early-stage unfavorable cHL, concomitant Nivo-AVD induces a high early CR rate. The interim CR rate observed with 4x nivolumab monotherapy is higher than previously reported in relapsed or advanced-stage disease. The primary endpoint and initial PFS data will be reported at the meeting. Disclosures Bröckelmann: Bristol-Myers Squibb: Honoraria, Other: Travel Support, Research Funding; Takeda: Consultancy, Honoraria, Other: Travel Support, Research Funding; MSD Sharpe & Dohme: Research Funding. Kerkhoff:EUSA: Honoraria; Hexal: Honoraria; Celgene: Honoraria, Other: Travel Support; Roche: Honoraria; Novartis: Honoraria. Hüttmann:University Hospital Essen: Employment; Takeda: Honoraria; Gilead: Honoraria. Zimmermann:Takeda: Honoraria, Other: Travel Expenses; Novartis: Other: Travel Expenses; MSD: Other: Travel Expenses; BMS: Other: Travel Expenses. von Tresckow:MSD Sharpe & Dohme: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Pfizer: Honoraria; Roche: Honoraria; Amgen: Honoraria. Klapper:Roche, Takeda, Amgen, Regeneron: Honoraria, Research Funding. Borchmann:Novartis: Honoraria, Research Funding. OffLabel Disclosure: Nivolumab 240mg i.v. 2-weekly for 1st-line treatment of classical Hodgkin lymphoma.
- Published
- 2019
48. Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial
- Author
-
Horst Mueller, Jasmin Mettler, Paul J Bröckelmann, Conrad-Amadeus Voltin, Andreas Engert, Carsten Kobe, Christian Baues, Peter Borchmann, Michael Fuchs, and Markus Dietlein
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Dacarbazine ,medicine.medical_treatment ,Immunology ,Population ,Phases of clinical research ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,parasitic diseases ,Medicine ,Stage (cooking) ,education ,education.field_of_study ,Chemotherapy ,business.industry ,Cell Biology ,Hematology ,Debulking ,Chemotherapy regimen ,030104 developmental biology ,Nivolumab ,business ,030215 immunology ,medicine.drug - Abstract
Background: Metabolic tumor volume (MTV) measured by FDG-PET/CT is becoming established as an independent risk factor for treatment failure in Hodgkin lymphoma (HL). Moreover, response to treatment with novel agents including checkpoint inhibitors may be better reflected by a decrease in MTV than by currently used response criteria. Our aim was to evaluate the early response to first-line HL treatment with the PD-1 inhibitor nivolumab using MTV. Methods: The analysis set included 59 patients with newly diagnosed, early-stage unfavorable HL treated within the prospective, multicenter, open label, randomized, phase II NIVAHL trial of the German Hodgkin Study Group (GHSG). Patients in NIVAHL were randomized to receive either four double cycles of nivolumab, doxorubicin, vinblastine, and dacarbazine (4x Nivo-AVD, group A, n=31) or a sequential therapy starting with 4x nivolumab monotherapy followed by 2xNivo-AVD and 2x AVD (group B, n=28). Early response to treatment was assessed at a 1st interim restaging after either 2x Nivo-AVD or 4x nivolumab. All NIVAHL patients who underwent PET at both initial staging and early response assessment, with images available to the central review panel for quantitative analysis before April 30th 2019, were included. MTV was calculated using a fixed SUV threshold of 4 for both staging and restaging. Results: Patient characteristics of the MTV analysis subset presented here did not differ in any relevant way from the overall NIVAHL trial population. Median age of the 59 patients was 27 years (range 18-57) with a female predominance (61%). All patients presented with stage II disease (IIB 27%) and ≥3 involved areas was the most common risk factor (75%) followed by elevated erythrocyte sedimentation rate (51%), extranodal disease (17%) and large mediastinal mass (14%). Mean MTV at initial staging was 124 ml (range 4 - 578 ml) and 177 ml (11 - 581 ml) in groups A and B, respectively. In both groups a marked decrease in MTV was observed at the 1st interim restaging (Figure 1): After 2x Nivo-AVD all patients in group A showed a reduction of MTV >80% (mean percentage change in MTV -99.8%). In group B a reduction of MTV >80% was observed in 26/28 patients (93%), while in 2/28 patients an increase Using the Lugano criteria and a Deauville score of 4 or higher as cut-off for PET-positivity, early interim complete remission was observed in 81% of patients after 2xNivo-AVD, as compared to 51% after 4x nivolumab monotherapy. Further analyses regarding MTV and response at the 2nd and end-of-treatment restaging as well as survival data are not yet available due to limited follow-up. These data will be available at the time of presentation and shown at the meeting. Conclusions: Marked reductions of MTV demonstrate an excellent early efficacy for both 2x Nivo-AVD and 4x nivolumab as 1st-line therapy for early-stage unfavorable HL. The unexpectedly and previously unreported high MTV reduction with nivolumab monotherapy indicates a relevant potential of anti-PD1 mono- or debulking-therapy in the 1st-line treatment of early-stage unfavorable HL. Early interim response assessment based on MTV may help to identify HL patients treated with anti-PD1 antibodies in whom a significant reduction or even omission of chemotherapy could be considered. MTV appears to have the potential to accurately measure response to immune checkpoint inhibition. However, correlation of early MTV reduction with response at the end of treatment or with survival data is pending. Disclosures Borchmann: Novartis: Honoraria, Research Funding. Bröckelmann:Bristol-Myers Squibb: Honoraria, Other: Travel Support, Research Funding; Takeda: Consultancy, Honoraria, Other: Travel Support, Research Funding; MSD Sharpe & Dohme: Research Funding.
- Published
- 2019
49. Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial
- Author
-
Stephan Mathas, Julia Meissner, Richard Greil, Annette Plütschow, Andreas Zimmermann, Michael Fuchs, Felicitas Thol, Paul J Bröckelmann, Christian Baues, Alexander Fosså, Josée M. Zijlstra, Andreas Engert, and Timothy M Illidge
- Subjects
Oncology ,medicine.medical_specialty ,Palliative care ,Chlorambucil ,business.industry ,medicine.medical_treatment ,Immunology ,Abscopal effect ,Cell Biology ,Hematology ,Pembrolizumab ,Biochemistry ,Radiation therapy ,Internal medicine ,Refractory Hodgkin Lymphoma ,Medicine ,Nivolumab ,Stage (cooking) ,business ,medicine.drug - Abstract
Background The anti-PD1 antibodies nivolumab and pembrolizumab are approved for relapsed or refractory classical Hodgkin lymphoma (r/r cHL) due to high overall response rates (ORR) with a favorable safety profile. However, complete responses (CR) are rare, and patients eventually develop progressive disease. Treatment options in this situation are very limited and usually regarded palliative. Innovative therapies for patients with progressive r/r cHL or insufficient response to anti-PD1 antibodies are hence an unmet clinical need. Radiotherapy (RT) is highly effective and potentially curative in cHL. Local RT results in immunogeneic cell-death at times leading to immune-mediated systemic effects termed abscopal response (AR). Case reports in different cancers including cHL highlight this effect of local therapies potentially enhanced by systemic immunotherapies. Combining the approved systemic anti-PD1 treatment with local RT to a single cHL lesion might hence work synergistically and result in improved tumor control with limited additional toxicity. It thereby would constitute a viable therapeutic option for patients with r/r cHL and could in the future also be incorporated in earlier lines of therapy. However, prospective data regarding this treatment strategy is lacking and will be generated with the recently activated herein presented GHSG AERN trial. Study Design & Methods AERN is an investigator-sponsored, prospective, international, multicenter, single-arm, two-stage phase II trial (NCT03480334) conducted at 10 European trial sites in Austria, Germany, United Kingdom, Netherlands and Norway. Patients with r/r cHL on active anti-PD1 therapy >18 years of age without serious concomitant diseases or organ dysfunction are eligible for enrollment. Patients either have to present with progressive disease (PD) or stable disease (SD) >6 months as best response to the ongoing anti-PD1 antibody. After registration for the screening phase, eligibility will be verified by a centralized GHSG review facility who will also define a single target lesion for RT to ensure at least one cHL lesion outside the 10% RT isodose for evaluation of the primary endpoint (abscopal response rate after 6x nivolumab, ARR-6). All patients will receive 240mg nivolumab at 2-weekly intervals and 20 Gy RT to the target lesion at 2 Gy fractions on ten consecutive working days starting day 6 of nivolumab treatment. Nivolumab will be discontinued in case of inacceptable toxicity or further disease progression and continued for a maximum of 18 months within the AERN trial. During the first stage of the trial, 9 qualified patients will be treated and their response to treatment will be centrally evaluated after the first 6 nivolumab doses. If no AR is observed in stage I, the trial will be terminated for futility. Otherwise 20 additional patients will be enrolled into the second stage for a total trial population of 29 r/r cHL patients. The null hypothesis H0: ARR-6 < 5% will be tested against a one-sided alternative at a confidence level of α = 5%, and at least 4 AR need to be observed for the rejection of H0. Secondary endpoints include e.g. ORR, overall ARR, CR rate, PFS and OS but also feasibility aspects, (S)AEs and quality of life (QoL) measures. To understand the underlying mechanisms of efficacy but also resistance or toxicity a comprehensive set of correlative studies will be conducted. Baseline and sequential blood samples as well as tumor biopsies and rectal swabs for microbiome analyses will be taken during AERN in patients with separate informed consent. This allows detailed evaluation of serological, cellular, functional, histological and genetic parameters to elucidate synergies between anti-PD1 and RT. Ultimately the correlative studies should help to further refine anti-PD1 based combination therapies, ideally beyond the setting of r/r cHL. In summary AERN, to our knowledge, is the first prospective trial formally evaluating the postulated abscopal effect in r/r cHL. The trial addresses an unmet clinical need in r/r cHL patients with insufficient or lost response to anti-PD1 antibodies. AERN additionally will provide proof-of-concept for a synergy of local RT with checkpoint inhibition substantiated by comprehensive correlative studies in blood, tumor tissue and microbiome. Recruitment has started but preliminary data regarding safety or efficacy are not yet available. Figure Disclosures Bröckelmann: MSD Sharpe & Dohme: Research Funding; Takeda: Consultancy, Honoraria, Other: Travel Support, Research Funding; Bristol-Myers Squibb: Honoraria, Other: Travel Support, Research Funding. Greil:Amgen: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Celgene: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Eisai: Honoraria; Mundipharma: Honoraria, Research Funding; Merck: Consultancy, Honoraria, Research Funding; Ratiopharm: Research Funding; Gilead: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Janssen-Cilag: Honoraria; Sanofi Aventis: Honoraria; MSD: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Sandoz: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Genentech: Honoraria, Research Funding; GSK: Research Funding; Daiichi Sankyo: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Other: Travel/accomodation expenses, Research Funding; Boehringer Ingelheim: Honoraria. Zijlstra:Janssen: Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Illidge:Div of Cancer Sciences, Faculty of Biology, Medicine and Health, Univ of Manchester, National Institutes of Health and Research Biomedical Research Center, Manchester Academic Health Sciences, Christie Hospital National Health Service Foundation Trust: Employment; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Seattle Genetics, Inc.: Research Funding. Zimmermann:Takeda: Honoraria, Other: Travel Expenses; Novartis: Other: Travel Expenses; MSD: Other: Travel Expenses; BMS: Other: Travel Expenses.
- Published
- 2019
50. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
- Author
-
Lena Schröder, Andreas Engert, Volker Diehl, Boris Böll, Annette Plütschow, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, and Michael Fuchs
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Immunology ,Salvage therapy ,Biochemistry ,Gastroenterology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Autologous stem-cell transplantation ,Antineoplastic Agents, Immunological ,Refractory ,Internal medicine ,Germany ,medicine ,Humans ,Lymphocytes ,Survival analysis ,Aged ,Aged, 80 and over ,Salvage Therapy ,Chemotherapy ,business.industry ,Cell Biology ,Hematology ,Middle Aged ,Chemotherapy regimen ,Combined Modality Therapy ,Hodgkin Disease ,Survival Analysis ,Radiation therapy ,030220 oncology & carcinogenesis ,Rituximab ,Female ,Neoplasm Recurrence, Local ,business ,030215 immunology ,medicine.drug ,Follow-Up Studies ,Stem Cell Transplantation - Abstract
The optimal treatment of patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is ill defined. To shed more light on treatment options and outcome, we performed an analysis using the database of the German Hodgkin Study Group (GHSG). Ninety-nine patients who had received first-line treatment within 12 prospective GHSG studies conducted between 1993 and 2009, and subsequently developed disease recurrence (n = 91) or had primary disease progression (n = 8), were included. At initial NLPHL diagnosis, the median age was 40 years and 76% of patients were male. First-line treatment consisted of radiotherapy (RT) alone (20%), chemotherapy with or without RT (74%), and the anti-CD20 antibody (Ab) rituximab (6%), respectively. The median follow-up from initial diagnosis was 11.2 years. The median time to disease recurrence was 3.7 years. The applied salvage approaches included single-agent anti-CD20 Ab treatment or RT alone (37%), conventional chemotherapy (CT) with or without anti-CD20 Ab treatment with or without RT (27%) and high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) (31%). No salvage treatment was given in 4% of patients. The 5-year progression-free survival and overall survival estimates after NLPHL recurrence were 75.6% and 89.5% (74.1% and 97.2% after single-agent anti-CD20 Ab treatment or RT alone; 68.0% and 77.8% after CT with or without anti-CD20 Ab treatment with or without RT; 84.6% and 89.8% after HDCT and ASCT). Hence, patients with relapsed or refractory NLPHL had a good overall prognosis. Factors such as time to disease recurrence and previous treatment may guide the choice of the optimal salvage approach for the individual patient.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.